产品名称	TTA1人甲状腺癌细胞
货号	ZQ0281
产品介绍	人甲状腺未分化癌细胞（anaplastic thyroid carcinoma, ATC），未分化。
种属	人
性别/年龄	男/64岁
组织	甲状腺
疾病	间变性甲状腺癌
细胞类型	肿瘤细胞
形态学	成纤维细胞
生长方式	贴壁
倍增时间	大约28.8小时
培养基和添加剂	DMEM高糖（中乔新舟  货号：ZQ-100）+10%FBS（中乔新舟  货号：ZQ500-A)+1%P/S（中乔新舟  货号：CSP006）
推荐完全培养基货号	ZM0281
生物安全等级	BSL-1
STR位点信息	Amelogenin：X CSF1PO： 10,11 D3S1358：15 D5S818： 12,13 D7S820： 11,12 D8S1179：13,15 D13S317：12 D16S539：9,10 D18S51：15 D21S11：30 FGA：23 TH01：6 TPOX：11 vWA：17
培养条件	95%空气，5%二氧化碳；37℃
抗原表达/受体表达
基因表达
保藏机构	RCB；
供应限制	仅供科研使用

货号	ZQ0281
发货规格	活细胞：T25培养瓶*1瓶或者1ml 冻存管*1支（细胞量约为5 x 10^5 cells/vial）二选一
发货形式	活细胞：常温运输；冻存管：干冰运输
储存温度	活细胞：培养箱；冻存管：液氮罐
产地	中国
供应限制	仅供科研使用

论文标题： LncRNA PVT1 Acts as a Tumor Promoter in Thyroid Cancer and Promotes Tumor Progression by Mediating miR-423-5p-PAK3
DOI： 10.2147/CMAR.S283443
发表时间： 2020-12-30
期刊： Cancer Management and Research
影响因子： 2.886
货号： ZQ0281
产品名称： TTA1 cells

原文链接： https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779291/

PubMed=8121182; DOI=10.1002/jso.2930550209
Yoshida A., Asaga T., Masuzawa C., Kawahara S., Yanoma S., Harada M., Okamoto T.
Production of cytokines by thyroid carcinoma cell lines.
J. Surg. Oncol. 55:104-107(1994)

PubMed=8176927; DOI=10.1002/jso.2930550308
Yoshida A., Asaga T., Masuzawa C., Kawahara S.
Alteration of tumorigenicity in undifferentiated thyroid carcinoma cells by introduction of normal chromosome 11.
J. Surg. Oncol. 55:170-174(1994)

PubMed=9177455; DOI=10.1016/S0304-3835(97)04742-3
Satake S., Sugawara I., Watanabe M., Takami H.
Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines.
Cancer Lett. 116:33-39(1997)

PubMed=15613457; DOI=10.1677/erc.1.00818
Onda M., Emi M., Yoshida A., Miyamoto S., Akaishi J., Asaka S., Mizutani K., Shimizu K., Nagahama M., Ito K., Tanaka T., Tsunoda T.
Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes.
Endocr. Relat. Cancer 11:843-854(2004)

PubMed=16924234; DOI=10.1038/sj.onc.1209899
Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.
A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
Oncogene 26:1178-1187(2007)

PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

Patent=US8029793
Yoshida A., Yanoma S., Hirose F.
Methods for inhibiting cell proliferation.
Patent number US8029793, 04-Oct-2011

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)